Pneumologia

Nova diretriz no Reino Unido | Autoisolamento para pessoas com COVID-19 pode encerrar após 5 dias completos e 2 testes rápidos negativos – “O período padrão de autoisolamento continua sendo de 10 dias, e o paciente só deve deixá-lo precocemente depois de fazer 2 testes rápidos e não ter febre, conforme a orientação.”

17 Jan, 2022 | 13:21h

Self-isolation for those with COVID-19 can end after 5 full days following 2 negative LFD tests – Department of Health and Social Care

 

Comentário no Twitter (fio – clique para saber mais)

Self-isolation period for people infected with COVID in England will be reduced to 5 days from Monday 17 Jan. But it's conditional: 2 NEGATIVE tests on days 5 & 6, & no symptoms, & not in certain high risk situations e.g. working with vulnerable people
1/https://t.co/HLxlIbpbkR

— Andrew Lee (@andrewleedr) January 13, 2022

 

---

Fluvoxamina para Covid-19: o que médicos e farmacêuticos precisam saber.

17 Jan, 2022 | 13:14h

Fluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario

Conteúdos relacionados:

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Comentário no Twitter

Thinking of prescribing fluvoxamine for covid 19? Ontario has a nice infographichttps://t.co/MKT8PqlJpM

— Todd Lee (@DrToddLee) January 12, 2022

 

---

Estudo randomizado | Colchicina não reduz significativamente a necessidade de intubação ou a mortalidade em 28 dias em pacientes internados com Covid-19.

17 Jan, 2022 | 13:13h

Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial – JAMA Network Open

Conteúdos relacionados:

M-A: Colchicine doesn’t lessen COVID-19 severity or stave off risk of death.

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

 

Comentário no Twitter

This randomized clinical trial found that colchicine did not significantly reduce mechanical ventilation or mortality in patients hospitalized with #COVID19 pneumonia. @DLBhattMD https://t.co/2nU5Ks74uF pic.twitter.com/VvHhTFnBhV

— JAMA Network Open (@JAMANetworkOpen) December 29, 2021

 

---

Estudo de coorte | Pacientes que perderam peso via cirurgia bariátrica podem estar sob menor risco de ter Covid-19 grave, em comparação a pacientes não submetidos a intervenção cirúrgica como tratamento de sua obesidade.

17 Jan, 2022 | 13:11h

Association of Weight Loss Achieved Through Metabolic Surgery With Risk and Severity of COVID-19 Infection – JAMA Surgery

Comentários:

Is COVID-19 the Newest Comorbidity of Obesity Mitigated by Bariatric Surgery? – JAMA Surgery

Can weight loss help protect against Covid-19? – CNN

---

Perspectiva | Ômicron está nos forçando a repensar sobre COVID leve.

17 Jan, 2022 | 13:10h

Omicron Is Forcing Us to Rethink Mild COVID – The Atlantic

---

Estudo mostra que as vacinas contra COVID-19 oferecem proteção duradoura contra internações e morte.

13 Jan, 2022 | 21:23h

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines – New England Journal of Medicine

Comunicado de imprensa: Study shows COVID-19 vaccines offer lasting protection – University of North Carolina at Chapel Hill

---

Estudo observacional em adolescentes mostrou que a vacina da Pfizer-BioNTech teve uma efetividade geral de 94% contra internações e de 98% contra Covid-19 grave.

13 Jan, 2022 | 21:22h

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents – New England Journal of Medicine

Editorial: Sparing of Severe Covid-19 in Vaccinated Adolescents – New England Journal of Medicine

---

Um estudo observacional na África do Sul estima que a vacina da Pfizer tenha uma efetividade de 70% contra internação por Covid-19 causada pela variante Ômicron.

13 Jan, 2022 | 21:20h

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa – New England Journal of Medicine

Comentário: BNT162b2 still effective, but less so, against Omicron – HealthDay

---

Estudo randomizado | Rendesivir iniciado precocemente em pacientes ambulatoriais pode prevenir a progressão para Covid-19 grave.

13 Jan, 2022 | 21:18h

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients – New England Journal of Medicine

Editorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?

Comentário: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress

 

Comentário no Twitter

Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. #COVID19 #IDTwitter https://t.co/YFflw5nBxB pic.twitter.com/4NCD9AcnYH

— NEJM (@NEJM) December 22, 2021

 

---

Células imunológicas “killer” ainda reconhecem a variante Ômicron.

13 Jan, 2022 | 21:16h

‘Killer’ immune cells still recognize Omicron variant – Nature

Ver também: T-cells: the superheroes in the battle against omicron – The Conversation

---